GlassScriptPhysician profile
David Guerrero
NPI 1265561849
$7,923.01
in general payments reported to CMS, 2019-2025
47 companies · $1,189 in 2025
The $1,189 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,151 · 2020: $1,250 · 2021: $1,280 · 2022: $799 · 2023: $1,166 · 2024: $1,089 · 2025: $1,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,349 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,348.90 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,268.25 | 2019-2025 | Ozempic, Rybelsus, Sogroya |
| Janssen Pharmaceuticals, INC | $751.86 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $710.37 | 2021-2025 | Jardiance, Mounjaro, Kisunla |
| Astellas Pharma US INC | $549.77 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $430.72 | 2019-2025 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $350.51 | 2019-2022 | |
| Abbott Laboratories | $328.17 | 2019-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $317.76 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Allergan, INC. | $273.32 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.02 | 2020-2025 | Xifaxan |
| Lundbeck LLC | $240.05 | 2022-2025 | Rexulti, Brintellix |
| Otsuka America Pharmaceutical, INC. | $237.88 | 2022-2025 | Rexulti, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $207.41 | 2021-2025 | |
| Abiomed | $164.41 | 2024 | Impella |
| Pfizer INC. | $162.22 | 2019-2024 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Guerrero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.